AIC
TVRD

Ameritas Investment Company’s Tvardi Therapeutics TVRD Stock Holding History

Ameritas Investment Company’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8
Closed -$5.91K – 2141
2021
Q1 		$5.91K Buy
+8
New +$5.48K ﹤0.01% 1667
2020
Q2 		– Sell
-27
Closed -$13K – 1650
2020
Q1 		$13K Buy
+27
New +$14.7K ﹤0.01% 1139
2019
Q4 		– Sell
-50
Closed -$33K – 1552
2019
Q3 		$33K Buy
+50
New +$41.6K 0.01% 782

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Ameritas Investment Company's TVRD Position: Q2 2021 in Review

Ameritas Investment Company sold out of Tvardi Therapeutics (TVRD) in Q2 2021, closing a stake of 8 shares — an estimated $5.91K sold.

Ameritas Investment Company first reported a position in TVRD in Q3 2019 and held it in 3 quarters. The position peaked at $33K in Q3 2019. 173 funds tracked by Wall St. Rank hold TVRD as of Q2 2021.

  • Ameritas Investment Company reported no remaining Tvardi Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Company sold 8 Tvardi Therapeutics shares in Q2 2021, an estimated $5.91K.
  • Ameritas Investment Company first reported a position in Tvardi Therapeutics in Q3 2019 and held it in 3 quarters.
  • Ameritas Investment Company's Tvardi Therapeutics position peaked at $33K in Q3 2019.
  • 173 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2021.

Based on Ameritas Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.